How I Treat Hodgkin Lymphoma
Nancy L. Bartlett, MD, Washington University School of Medicine in St. Louis
Friday, September 8, 2017 2:00 p.m.
Fairmont Chicago, Millennium Park, Chicago, IL
Despite the high cure rate of Hodgkin lymphoma (HL), decisions regarding therapy for individual patients aimed at optimizing outcome while minimizing acute toxicity and late effects remain challenging. The role of consolidative radiotherapy in early stage disease remains controversial, and clinical prognostic markers including interim and end of treatment PET scans have provided an imperfect approach to risk-based therapy. Incorporation of new and perhaps less toxic agents such as brentuximab vedotin or PD1 inhibitors into earlier lines of therapy is under investigation. Dr. Bartlett will discuss interim PET directed front-line treatment approaches to HL and the utilization of new agents in relapsed HL.
About the Speaker
Nancy L. Bartlett, MD, is Professor of Medicine and the Koman Endowed Chair in Medical Oncology at the Siteman Cancer Center at Washington University in St. Louis. She is Co-Chair of the Alliance Cooperative Group Lymphoma Committee and serves on the Alliance Board of Directors. Her research interests include clinical trials in both non-Hodgkin and Hodgkin lymphoma. Currently, she is involved in the design and/or conduct of multiple trials of brentuximab vedotin in HL and DLBCL, interim PET studies in HL and NHL, ibrutinib studies in FL, DLBCL, and MCL, CAR-T cell therapy in DLBCL, CD20 bi-specific antibody in NHL, and novel immunotherapy approaches to both NHL and HL.
back to top